The Use of N-Terminal-Pro-BNP in Preterm Infants
- PMID: 20069108
 - PMCID: PMC2804037
 - DOI: 10.1155/2009/175216
 
The Use of N-Terminal-Pro-BNP in Preterm Infants
Abstract
The use of natriuretic peptides in the neonatal population is emerging. B-type Natriuretic Peptide (BNP) and N-terminal-Pro-BNP (NTpBNP) are used in the adult population to assess myocardial function and volume loading. Their role in prognosis following cardiac surgery has also been identified. In preterm infants NTpBNP is becoming increasingly recognised as a potential screening tool for patent ductus arteriosus (PDA), and a marker for myocardial performance. In addition, NTpBNP may provide prognostic information in preterm infants and term infants with congenital diaphragmatic hernia (CDH). In this paper, the role of NTpBNP in the preterm population will be discussed.
References
- 
    
- Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA. The amino-terminal portion of Pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochemical and Biophysical Research Communications. 1995;214(3):1175–1183. - PubMed
 
 - 
    
- Maack T. Receptors of atrial natriuretic factor. Annual Review of Physiology. 1992;54:11–27. - PubMed
 
 - 
    
- Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacology and Therapeutics. 2004;102(3):223–241. - PubMed
 
 
LinkOut - more resources
Full Text Sources
